Adults With Blood Cancers More Likely to Respond to Booster Rather Than Initial Dose of COVID-19 Vaccine

People with hematologic malignancies, such as leukemia, lymphoma and multiple myeloma, have an impaired immune system due to their disease and its treatment, putting them at risk for severe COVID-19 infection and experiencing a reduced response to COVID-19 vaccination. In a study published online in the journal Cancer (published online July 11, 2022), less than half of patients with hematologic malignancies mounted detectable antibodies after initial COVID-19 vaccination, but 56% of